Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM

The effect of delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) on the Multiple Sclerosis Functional Composite (MSFC) was assessed using integrated Phase 3 DEFINE and CONFIRM data. Patients treated with DMF (n = 769) demonstrated significant superiority on the MSFC, and eac...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis journal - experimental, translational and clinical translational and clinical, 2016-01, Vol.2, p.2055217316634111-2055217316634111
Main Authors: Giovannoni, Gavin, Gold, Ralf, Kappos, Ludwig, Arnold, Douglas L, Bar-Or, Amit, Marantz, Jing L, Yang, Minhua, Lee, Andrew
Format: Article
Language:English
Subjects:
Multiple sclerosis
Short Report
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The effect of delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) on the Multiple Sclerosis Functional Composite (MSFC) was assessed using integrated Phase 3 DEFINE and CONFIRM data. Patients treated with DMF (n = 769) demonstrated significant superiority on the MSFC, and each component, compared with placebo (n = 771) over two years: mean change for DMF vs placebo was 0.054 vs −0.053 on MSFC; −0.088 vs −0.286 on Timed 25-Foot Walk, 0.047 vs 0.003 on 9-Hole Peg Test and 0.178 vs 0.123 on Paced Auditory Serial Addition Test. DMF was an efficacious treatment for patients with MS.
ISSN:2055-2173
2055-2173
DOI:10.1177/2055217316634111